These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26959746)

  • 1. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.
    Quinn BA; Wang S; Barile E; Das SK; Emdad L; Sarkar D; De SK; Morvaridi SK; Stebbins JL; Pandol SJ; Fisher PB; Pellecchia M
    Oncotarget; 2016 Mar; 7(13):17103-10. PubMed ID: 26959746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
    Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
    J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer.
    Nesbitt H; Sheng Y; Kamila S; Logan K; Thomas K; Callan B; Taylor MA; Love M; O'Rourke D; Kelly P; Beguin E; Stride E; McHale AP; Callan JF
    J Control Release; 2018 Jun; 279():8-16. PubMed ID: 29653222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
    Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
    Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
    Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
    Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
    Lee GY; Qian WP; Wang L; Wang YA; Staley CA; Satpathy M; Nie S; Mao H; Yang L
    ACS Nano; 2013 Mar; 7(3):2078-89. PubMed ID: 23402593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
    Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
    Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
    Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
    Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
    Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
    Zhang GN; Liang Y; Zhou LJ; Chen SP; Chen G; Zhang TP; Kang T; Zhao YP
    Cancer Lett; 2011 Dec; 313(2):137-44. PubMed ID: 22030254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
    Hasnis E; Alishekevitz D; Gingis-Veltski S; Bril R; Fremder E; Voloshin T; Raviv Z; Karban A; Shaked Y
    Neoplasia; 2014 Jun; 16(6):501-10. PubMed ID: 24957319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.
    Gang J; Park SB; Hyung W; Choi EH; Wen J; Kim HS; Shul YG; Haam S; Song SY
    J Drug Target; 2007 Jul; 15(6):445-53. PubMed ID: 17613663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
    Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.